Skin Conditions & Dermatology Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

This Phase 3 trial focuses on the long-term safety and effectiveness of dupilumab, a biologic treatment, for children from 6 months up to 18 years old who have atopic dermatitis. If the results continue to support its use, dupilumab could become a reliable treatment option for managing this chronic skin condition in pediatric patients, helping to control symptoms while maintaining manageable side effects. The study is active but not recruiting, with sites in the United States and Europe.

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

This Phase 4 study explored the skin biology of people with mild to moderate-severe atopic dermatitis by analyzing skin samples alongside treatments such as dupilumab and topical steroids. By understanding different skin types and how they respond to treatments, this research could lead to more personalized and effective care for patients. The study included 433 participants across 10 locations in the United States and has completed with results now available.

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

This completed Phase 3 trial tested the oral medication upadacitinib in adolescents and adults with moderate to severe atopic dermatitis. If proven effective, upadacitinib may offer an additional treatment option that can improve symptom control and quality of life for those needing systemic therapy. The study enrolled over 900 participants worldwide and results are available.

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

This Phase 4 trial assessed the impact of deucravacitinib, an oral drug, on quality of life for adults living with plaque psoriasis. Conducted in community settings across the United States and Puerto Rico with 180 participants, the study aims to confirm if this medication provides an easier and effective treatment option outside hospital environments. Results from this study are available.

Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions

This ongoing study in France is developing a diagnostic test to predict which precancerous skin lesions are likely to progress to cancer. By identifying lesions that need early removal versus those that may regress, this test could help patients avoid unnecessary surgeries and focus treatment where it is most needed. The trial is recruiting and involves 140 participants.

This week showed promising advances in treatments and diagnostics for atopic dermatitis, psoriasis, and precancerous skin conditions. The availability of long-term safety data for pediatric use of dupilumab and new oral options like upadacitinib and deucravacitinib could expand patient choices. Meanwhile, improved understanding of skin biology and diagnostic tools may further personalize care and reduce unnecessary procedures. TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.